Previous close | 41.69 |
Open | 45.97 |
Bid | 41.88 x 0 |
Ask | 42.01 x 0 |
Day's range | 41.74 - 42.20 |
52-week range | 41.69 - 63.00 |
Volume | |
Avg. volume | 68 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 26 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
PRINCETON, N.J., April 26, 2024--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine....
A Strategic SWOT Insight into Bristol-Myers Squibb's Financials and Future